WHO recommends artemisinin-based combination therapies for treating uncomplicated malaria, alongside studies to monitor treatment effectiveness. Given the threat of antimalarial resistance, including partial resistance in several African countries, molecular tools are vital for tracking resistance. ...In 2015, WHO launched the External Quality Assessment scheme for nucleic acid amplification testing to ensure reliable lab results. Coordinated by WHO and operated by the United Kingdom National External Quality Assessment Service for Parasitology, the scheme provides quality-controlled specimens and reports to help improve testing accuracy. Experts recently discussed expanding the scheme to include antimalarial resistance markers.
more
The following appendices of the Guide for introducing a malaria vaccine containing key messages are available for country adaptation
WHO position paper on malaria vaccines, Weekly Epidemiological Record 10 May 2024
The WHO susceptibility test kit has been extensively used for monitoring of insecticide resistance in disease vectors for many years. Over the years, users have reported issues with these kits and potential improvements to WHO in an ad-hoc manner. To systematically determine whether the reported iss...ues were widespread and to collate potential improvements to the kit, a survey of users was put online from 30 June to 15 October 2023. The results from this survey are reported in this report.
more
Countries that have achieved at least 3 consecutive years of zero indigenous cases are eligible to apply for a WHO certification of malaria-free status.
Explore a world of health data
These guidelines promote the delivery of people-centred health services for STIs by providing evidence-based recommendations related to decentralization, integration, task sharing and digital health. These recommendations complement existing WHO guidelines for STI testing, treatment and management, ...and other service delivery interventions, such as self-care interventions. All the recommendations will be incorporated into the forthcoming WHO consolidated guidelines on STI prevention and care.
more
This document highlights the latest WHO recommendations designed to optimize health outcomes, streamline delivery and address persistent barriers to prevention and care. It especially focuses on people often left behind in service delivery, including adolescents and young people, key populations and... people with advanced HIV disease. The guidance emphasizes integration, simplification, choice and equity.
more
Scope: The purpose of this guideline is to assist health care providers caring for patients with suspected or confirmed arboviral disease caused by dengue, chikungunya, Zika or yellow fever viruses. This guideline includes recommendations on the management of patients admitted to health care facilit...ies (defined for the purpose of this guidance as “severe disease”) and those seen in outpatient facilities (defined for the purpose of this guidance as “non-severe disease”).
Target audience: This guideline is designed primarily for health care providers who manage patients with clinically apparent arboviral infections. The guideline can be applied at all levels of the health system, including community-based care, primary care, emergency departments and hospital wards.
more
Access to safe, effective and quality-assured health products and technologies is crucial for achieving universal health coverage and primary health care goals. The continued growth of the aging population; increasing burden of noncommunicable diseases; growing burden of mental health issues; climat...e change; shifting patterns of vector borne diseases, fungal disease and waterborne diseases; antimicrobial resistance; and new infectious hazards create an ongoing need for equitable access to safe, effective and quality-assured health products and technologies, and renewed investments in research and development for innovative health products and technologies.
The coronavirus pandemic exposed the inequalities in access to health products, highlighting the need for longer-term strategies to strengthen access to health products and technologies outside of and in emergency situations. While technological and scientific advances present an opportunity to increase access to health products and technologies, the risk of increasing inequality due to higher prices for new health products and technologies; the persisting problem of substandard and falsified medical products; a lack of skilled workforce in many low- and middle-income countries; and a lack of data for decisionmaking and for measuring progress present significant challenges.
more
8th IAS Conference on HIV Pathogenesis 19-22 July 2015 Vancouver
Anita Sands Prequalification Team – Diagnostics Essential Medicines and Health Product
This interim guidance to national health authorities and blood transfusion services outlines the steps required to collect convalescent whole blood (CWB) or plasma (CP) from Ebola virus disease (EVD) recovered patients for transfusion to patients with early EVD, as an empirical treatment modality.
...
Document contents:
Guidance on donor selection, screening, donation and handling of blood and plasma units;
guidance on transfusion of convalescent whole blood or plasma;
other considerations.
more
TECHNICAL NOTE III
WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2017